Vuslat Yilmaz

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4698130/publications.pdf

Version: 2024-02-01

63 papers	1,101 citations	471509 17 h-index	434195 31 g-index
64 all docs	64 docs citations	64 times ranked	1728 citing authors

#	Article	IF	Citations
1	IL-12 and IL-10 polymorphisms and their effects on cytokine production. Cytokine, 2005, 30, 188-194.	3.2	144
2	Identification of multiple independent susceptibility loci in the HLA region in BehÃ§et's disease. Nature Genetics, 2013, 45, 319-324.	21.4	130
3	Takayasu's arteritis is associated with HLA-B*52, but not with HLA-B*51, in Turkey. Arthritis Research and Therapy, 2012, 14, R27.	3.5	60
4	Activation of the JAK/STAT pathway in Behcetâ€™s disease. Genes and Immunity, 2015, 16, 170-175.	4.1	59
5	Interleukin (IL)â€“12, IL-2, and IL-6 Gene Polymorphisms in Takayasuâ€™s Arteritis from Turkey. Human Immunology, 2006, 67, 735-740.	2.4	47
6	Association of HLA-DRB1â^—14, -DRB1â^—16 and -DQB1â^—05 with MuSK-myasthenia gravis in patients from Turkey. Human Immunology, 2013, 74, 1633-1635.	2.4	43
7	Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK. PLoS ONE, 2015, 10, e0123546.	2.5	40
8	A putative functional variant within the UBAC2 gene is associated with increased risk of BehÃ§et's disease. Arthritis and Rheumatism, 2011, 63, 3607-3612.	6.7	39
9	Genetic heterogeneity within the HLA region in three distinct clinical subgroups of myasthenia gravis. Clinical Immunology, 2016, 166-167, 81-88.	3.2	38
10	Preferential production of IgG1, IL-4 and IL-10 in MuSK-immunized mice. Clinical Immunology, 2014, 151, 155-163.	3.2	35
11	Interleukin (IL)-12, IL-2, interferon-Î³ gene polymorphisms in subacute sclerosing panencephalitis patients. Journal of NeuroVirology, 2007, 13, 410-415.	2.1	27
12	B cells produce less IL-10, IL-6 and TNF-Î±in myasthenia gravis. Autoimmunity, 2015, 48, 201-207.	2.6	26
13	Comparison of Circulating Levels of Uremic Toxins in Hemodialysis Patients Treated with Medium Cut-Off Membranes and High-Flux Membranes: Theranova in Sisli Hamidiye Etfal (THE SHE) Randomized Control Study. Blood Purification, 2020, 49, 733-742.	1.8	26
14	Long Remission in Muscle-Specific Kinase Antibody-Positive Juvenile Myasthenia. Pediatric Neurology, 2009, 40, 455-456.	2.1	22
15	Common Denominators in the Immunobiology of IgG4 Autoimmune Diseases: What Do Glomerulonephritis, Pemphigus Vulgaris, Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura and Autoimmune Encephalitis Have in Common?. Frontiers in Immunology, 2020, 11, 605214.	4.8	21
16	Genetic Association of a Gainâ€ofâ€Function IFNGR1 Polymorphism and the Intergenic Region LNCAROD/DKK1 With BehÃ§etâ€™s Disease. Arthritis and Rheumatology, 2021, 73, 1244-1252.	5.6	21
17	Inflammation and regulatory T cell genes are differentially expressed in peripheral blood mononuclear cells of Parkinsonâ€™s disease patients. Scientific Reports, 2021, 11, 2316.	3.3	20
18	Immunization with Recombinantly Expressed LRP4 Induces Experimental Autoimmune Myasthenia Gravis in C57BL/6 Mice. Immunological Investigations, 2017, 46, 490-499.	2.0	19

#	Article	IF	Citations
19	Serum orexin-A levels are associated with disease progression and motor impairment in multiple sclerosis. Neurological Sciences, 2019, 40, 1067-1070.	1.9	19
20	Late-onset generalized myasthenia gravis: clinical features, treatment, and outcome. Acta Neurologica Belgica, 2020, 120, 133-140.	1.1	19
21	Regulatory B cells in myasthenia gravis are differentially affected by therapies. Annals of Clinical and Translational Neurology, 2018, 5, 1408-1414.	3.7	18
22	Polymorphisms of interferon-Î³, interleukin-10, and interleukin-12 genes in myasthenia gravis. Human Immunology, 2007, 68, 544-549.	2.4	17
23	Peripheral blood expression levels of inflammasome complex components in two different focal epilepsy syndromes. Journal of Neuroimmunology, 2020, 347, 577343.	2.3	16
24	IgG4 Autoantibodies in Organ-Specific Autoimmunopathies: Reviewing Class Switching, Antibody-Producing Cells, and Specific Immunotherapies. Frontiers in Immunology, 2022, 13, 834342.	4.8	14
25	Polymorphisms of the IL-8 and CXCR2 genes are not associated with BehÃ§et's disease. Journal of Rheumatology, 2005, 32, 93-7.	2.0	13
26	Elevated sTREM2 and NFL levels in patients with sepsis associated encephalopathy. International Journal of Neuroscience, 2023, 133, 327-333.	1.6	12
27	Effects of Teriflunomide on B Cell Subsets in MuSK-Induced Experimental Autoimmune Myasthenia Gravis and Multiple Sclerosis. Immunological Investigations, 2021, 50, 671-684.	2.0	11
28	The Association of PTPN22 R620W Polymorphism Is Stronger with Late-Onset AChR-Myasthenia Gravis in Turkey. PLoS ONE, 2014, 9, e104760.	2.5	10
29	miR-132-3p, miR-106b-5p, and miR-19b-3p Are Associated with Brain-Derived Neurotrophic Factor Production and Clinical Activity in Multiple Sclerosis: A Pilot Study. Genetic Testing and Molecular Biomarkers, 2021, 25, 720-726.	0.7	10
30	Increased Complement Consumption in MuSK-Antibody-Positive Myasthenia Gravis Patients. Medical Principles and Practice, 2011, 20, 581-583.	2.4	9
31	Impact of fingolimod on CD4+ T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients. Journal of Neuroimmunology, 2019, 337, 577065.	2.3	9
32	Peripheral blood memory B cell frequency predicts conversion from clinically isolated syndrome to multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 23, 9-14.	2.0	8
33	Enhanced NLRP3 and DEFA1B Expression During the Active Stage of Parenchymal Neuro-BehÃ§et's Disease. In Vivo, 2019, 33, 1493-1497.	1.3	8
34	Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 58, 103524.	2.0	8
35	Mannose-binding lectin pathway is not involved in myasthenia gravis pathogenesis. Journal of Neuroimmunology, 2009, 208, 40-45.	2.3	7
36	CSF levels of HoxB3 and YKL-40 may predict conversion from clinically isolated syndrome to relapsing remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 48, 102697.	2.0	7

#	Article	IF	Citations
37	Chemokine and Chemokine Receptor Polymorphisms in Bipolar Disorder. Psychiatry Investigation, 2016, 13, 541.	1.6	7
38	Prepubertal anti-Musk positive myasthenia gravis with long remission. Neuromuscular Disorders, 2014, 24, 36-39.	0.6	6
39	Relation of HLAâ€DRB1 to IgG4 autoantibody and cytokine production in muscleâ€specific tyrosine kinase myasthenia gravis (MuSKâ€MG). Clinical and Experimental Immunology, 2019, 197, 214-221.	2.6	6
40	Prompt Response to Prednisone Predicts Benign Course in MuSK-MG. European Neurology, 2017, 78, 137-142.	1.4	5
41	Expression of Akt1 and p-Akt1 in peripheral T cell subsets of multiple sclerosis patients. Acta Neurologica Belgica, 2020, 121, 1777-1782.	1.1	5
42	Cytokineâ€“chemokine and cognitive profile of multiple sclerosis patients with predominant optic nerve and spinal cord involvement. Journal of Spinal Cord Medicine, 2021, 44, 411-417.	1.4	5
43	Peripheral blood B cell subset ratios and expression levels of B cell-associated genes are altered in benign multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 52, 103019.	2.0	5
44	Sleep disturbance and cognitive decline in multiple sclerosis patients with isolated optic neuritis as the first demyelinating event. International Ophthalmology, 2020, 40, 151-158.	1.4	4
45	Adaptive immunity cells are differentially distributed in the peripheral blood of glycine receptor antibody-positive patients with focal epilepsy of unknown cause. Epilepsy Research, 2021, 170, 106542.	1.6	4
46	cFLIP overexpression in T cells in thymomaâ€associated myasthenia gravis. Annals of Clinical and Translational Neurology, 2015, 2, 894-905.	3.7	3
47	A Case of HaNDL with Low Cerebrospinal Fluid Level of Neurofilament Light Chain. Case Reports in Neurology, 2021, 12, 334-338.	0.7	3
48	Impact of autoimmune demyelinating brain disease sera on pericyte survival. Noropsikiyatri Arsivi, 2020, 58, 83-86.	0.3	3
49	CXCL13 Levels Indicate Treatment Responsiveness to Fingolimod in MS Patients. European Neurology, 2022, 85, 69-71.	1.4	3
50	Evaluation of Patients with Suspicion of COVID-19 in Pediatric Emergency Department. Sisli Etfal Hastanesi Tip Bulteni, 2021, 55, 179-187.	0.3	2
51	Acute ophthalmoparesis and persistent mydriasis: expanding the clinical spectrum of anti-gq1b positive cranial neuropathy in a 5.5-year-old girl. Turkish Journal of Pediatrics, 2019, 61, 794.	0.6	2
52	Classical complement pathway factor alterations in narcolepsy. Acta Neuropsychiatrica, 2022, 34, 212-219.	2.1	2
53	The treatment effect on peripheral B cell markers in antibody positive myasthenia gravis patients. Journal of Neuroimmunology, 2020, 349, 577402.	2.3	1
54	Serum anti-ganglioside antibodies in patients with autoimmune limbic encephalitis. Turkish Journal of Medical Sciences, 2021, , .	0.9	1

#	Article	IF	Citations
55	Flow Cytometry Analysis of Peripheral Blood B Cell Distribution of Patients with Multiple Sclerosis. Turk Noroloji Dergisi = Turkish Journal of Neurology, 2017, 23, 219-224.	0.3	1
56	Expression Levels of Inflammasome Complexes in Experimental Autoimmune Myasthenia Gravis Mouse Model (EAMG). Experimed, 2020, 9, 79-85.	0.1	1
57	Aquaporinâ€4 antibody seropositivity in myasthenia gravis patients with thymoma. Muscle and Nerve, 2013, 47, 306-307.	2.2	0
58	Differential cytokine changes in myasthenia gravis patients with antibodies against AChR and Musk. Journal of Neuroimmunology, 2014, 275, 212-213.	2.3	0
59	Viability of SH-SY5Y cells is associated with purinergic P2 receptor expression alterations. Acta Biologica Hungarica, 2017, 68, 22-34.	0.7	0
60	MO678DISTRIBUTION OF PERIPHERAL BLOOD T CELL SUBTYPESÂIN HEMODIALYSIS PATIENTS TREATED WITH MEDIUM CUT-OFF MEMBRANES AND HIGH-FLUXÂMEMBRANES. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
61	Impact of IntraventrÃcular Administration of SWAP-70 Antibody Positive Multiple Sclerosis Serum Antibodies on Motor Activity and Brain Histology. Experimed, 0, , .	0.0	0
62	B Cell Immunophenotyping and Expression Analysis of B Cell Specific Molecules of Patients with Benign Multiple Sclerosis. Experimed, 2020, 9, 105-112.	0.1	0
63	The Effect of Cognitive Rehabilitation on Peripheral Blood B Cell Distribution and Specific Gene Expression Levels in MS patients. , 2021, 1, 32-39.		0